Compare Tango Therapeutics Inc. (TNGX) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tango Therapeutics Inc. vs Viatris Inc — how do they compare? Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B), while Viatris Inc trades at $17.54 (market cap $20.05B). The key difference: Viatris Inc is far larger — about 5.4× Tango Therapeutics Inc.'s market cap, and Viatris Inc pays a 2.75% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Tango Therapeutics Inc. for 0 Days and Viatris Inc for 57 Days on average.
| TNGX | VTRS | |
|---|---|---|
Market Cap | $3.74B | $20.05B |
Volume | 3,438,781 | 8,682,135 |
Sector | Health | Health |
52-Week High | $32.90 | $18.27 |
52-Week Low | $7.50 | $9.98 |
Typical Hold Time | 0 Days | 57 Days |
Enterprise Value | $2.76B | $32.16B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Viatris (VTRS) trades at $17.25, down 1.65% today, with a bullish technical signal from moving averages. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.69 exceeding expectations. Revenue remains stable around $14.3B annually, though the company posted a net loss of $3.51B in 2025. Analyst consensus is mixed with 38% buy ratings and a $22.17 price target, representing 28% upside potential.
The outlook suggests potential upside from current levels if earnings momentum continues, supported by strong cash flow generation and dividend payments. Key risks include persistent negative profit margins, high debt levels, and competitive pressures in the generic drug market. The stock appears reasonably valued with P/S of 1.36x, but the elevated P/E of 236x reflects current profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
